DK1812015T3 - Methods for inhibition of nkt cells - Google Patents

Methods for inhibition of nkt cells

Info

Publication number
DK1812015T3
DK1812015T3 DK05851383.9T DK05851383T DK1812015T3 DK 1812015 T3 DK1812015 T3 DK 1812015T3 DK 05851383 T DK05851383 T DK 05851383T DK 1812015 T3 DK1812015 T3 DK 1812015T3
Authority
DK
Denmark
Prior art keywords
nkt cell
treatment
inhibition
methods
nkt cells
Prior art date
Application number
DK05851383.9T
Other languages
Danish (da)
English (en)
Inventor
Samuel Strober
Everett Hurteau Meyer
Dale T Umetsu
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of DK1812015T3 publication Critical patent/DK1812015T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK05851383.9T 2004-11-02 2005-11-02 Methods for inhibition of nkt cells DK1812015T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62456804P 2004-11-02 2004-11-02
US70654805P 2005-08-08 2005-08-08
PCT/US2005/040182 WO2006060117A2 (en) 2004-11-02 2005-11-02 Methods for inhibition of nkt cells

Publications (1)

Publication Number Publication Date
DK1812015T3 true DK1812015T3 (en) 2013-01-02

Family

ID=36565493

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05851383.9T DK1812015T3 (en) 2004-11-02 2005-11-02 Methods for inhibition of nkt cells

Country Status (11)

Country Link
US (2) US7682614B2 (enExample)
EP (1) EP1812015B1 (enExample)
JP (1) JP4948418B2 (enExample)
CN (1) CN101031307B (enExample)
AT (1) ATE539757T1 (enExample)
AU (1) AU2005310247A1 (enExample)
CA (1) CA2584971C (enExample)
DK (1) DK1812015T3 (enExample)
ES (1) ES2378076T3 (enExample)
PT (1) PT1812015E (enExample)
WO (1) WO2006060117A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002254396A1 (en) 2001-03-26 2002-10-08 Dana-Farber Cancer Institute, Inc. Method of attenuating reactions to skin irritants
EP2575824A4 (en) * 2010-05-24 2014-02-19 Childrens Medical Center METHOD FOR THE TREATMENT AND PREVENTION OF INFLAMMATORY DISEASES
DK2643346T3 (en) * 2010-11-25 2018-10-29 Imnate Sarl MODULATION OF ANTIGEN IMMUNOGENICITY BY ADDITION OF EPITOPES RECOGNIZED BY NKT CELLS
EP2731617A4 (en) 2011-07-12 2015-07-01 Brigham & Womens Hospital LIPID-BASED PSA COMPOSITIONS, METHOD FOR THEIR INSULATION AND USE METHOD THEREFOR
CN103945867B (zh) * 2011-10-27 2018-01-02 Nkt治疗公司 针对iNKT的人类化抗体
EP2906576B1 (en) 2012-10-12 2019-09-11 The Brigham and Women's Hospital, Inc. Glycosphingolipids and methods of use thereof
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
CA2910766C (en) 2013-04-30 2020-12-15 Otitopic Inc. Dry powder formulations and methods of use
JP6743051B2 (ja) 2015-01-27 2020-08-19 ラヴァ・セラピューティクス・ベー・フェー Ｃｄ１ｄを標的とする単一ドメイン抗体
CN108135167B (zh) 2015-08-19 2021-07-09 哈佛学院院长及董事 脂化psa组合物和方法
EP3484441A4 (en) 2016-07-15 2020-03-18 President and Fellows of Harvard College GLYCOLIPID COMPOSITIONS AND METHOD FOR USE
WO2019059953A2 (en) 2017-09-22 2019-03-28 Otitopic Inc. DRY POWDER COMPOSITIONS CONTAINING MAGNESIUM STEARATE
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
EP3853255A1 (en) 2018-09-19 2021-07-28 Lava Therapeutics B.V. Novel bispecific antibodies for use in the treatment of hematological malignancies
IL305579A (en) 2021-03-01 2023-10-01 Deciduous Therapeutics Inc Compounds for activating invariant natural killer T cells and methods for use in eliminating inflammatory senescent cells
EP4480486A1 (en) * 2022-02-14 2024-12-25 Riken Nkt cell ligand-containing liposome composition

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800738B1 (en) * 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US7063844B2 (en) * 1992-12-10 2006-06-20 The Brigham And Women's Hospital, Inc. Presentation of hydrophobic antigens to T-cells by CD1 molecules
US5679347A (en) * 1992-12-10 1997-10-21 Brigham And Women's Hospital Methods of isolating CD1-presented antigens, vaccines comprising CD1-presented antigens, and cell lines for use in said methods
DE69433115T2 (de) 1993-06-21 2004-04-01 Brigham And Women's Hospital, Boston Verfahren zur isolierung von cda-präsentierten antigenen, cd1-präsentierte antigeneenthaltende impfstoffe und in besagten verfahren verwendbare zelllinien
US6632976B1 (en) * 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
ATE421881T1 (de) * 1997-04-10 2009-02-15 Kyowa Hakko Kirin Co Ltd Nkt-zellenaktivatoren, die alpha-glycosylceramide enthalten
EP1011719A1 (en) * 1997-09-12 2000-06-28 Brigham & Women's Hospital Synthetic antigens for cd1-restricted immune responses
TW575420B (en) * 1997-09-22 2004-02-11 Kirin Brewery Composition for enhancing cellular immunogenicity comprising alpha-glycosylceramides
US6197582B1 (en) * 1998-03-18 2001-03-06 The Trustees Of Columbia University In The City Of New York Development of human monoclonal antibodies and uses thereof
AU4837499A (en) 1998-07-09 2000-02-01 Brian J. Nickoloff Method of treating disorders by modulating the interaction of natural killer receptors on t cells with their respective ligands
US20010051156A1 (en) * 2000-04-28 2001-12-13 Defu Zeng Methods for inhibition of polyclonal B cell activation and immunoglobulin class switching to pathogenic autoantibodies by blocking CD1-mediated interactions
WO2001094949A2 (en) 2000-06-05 2001-12-13 The Brigham And Women's Hospital, Inc. Soluble cd1 compositions and uses thereof
CN1444648A (zh) * 2000-06-06 2003-09-24 麒麟麦酒株式会社 扩增自然杀伤t细胞的方法
PT1297017E (pt) * 2000-06-19 2012-09-04 Gen Hospital Corp Composições e métodos de anticorpos monoclonais e policlonais específicos para subpopulações de célula t
US20020115624A1 (en) * 2000-06-22 2002-08-22 Behar Samuel M. Alpha gylcosylceramides for treating bacterial and fungal infections
WO2002016825A1 (fr) * 2000-08-18 2002-02-28 Mitsubishi Denki Kabushiki Kaisha Douille et transformateur pour lampe et procede de fabrication d'un transformateur pour lampe
DE10046658A1 (de) 2000-09-20 2002-04-04 Bosch Gmbh Robert Induktiver Übertrager und ein Verfahren zu dessen Herstellung
DE60131456T2 (de) * 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
IL140537A0 (en) * 2000-12-25 2002-02-10 Hadasit Med Res Service Educated nk t cells and their uses in the treatment of immune-related disorders
AU2002254396A1 (en) * 2001-03-26 2002-10-08 Dana-Farber Cancer Institute, Inc. Method of attenuating reactions to skin irritants
US6662434B2 (en) * 2001-04-03 2003-12-16 General Electric Company Method and apparatus for magnetizing a permanent magnet
US8178098B2 (en) * 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
CA2444429A1 (en) * 2001-04-11 2002-11-07 Atherogenics, Inc. Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality
US20020171538A1 (en) * 2001-05-15 2002-11-21 Kuo-Hsin Su Vehicle motion detector and control device arrangement
US20020171557A1 (en) * 2001-05-18 2002-11-21 Wegener William E. Security electronic system
JP2005500336A (ja) * 2001-07-25 2005-01-06 ニューヨーク・ユニバーシティ 感染および癌に対するワクチンのためのアジュバントとしてのグリコシルセラミドの使用
AU2003234443A1 (en) 2002-05-01 2003-11-17 Beth Israel Deaconess Medical Center Use of anti-cd1 antibodies for the modulation of immune responses
US7273852B2 (en) * 2002-06-13 2007-09-25 The Research Foundation Of The City University Of New York Synthetic C-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases
DE60239566D1 (de) 2002-06-14 2011-05-05 Brigham And Women S Hospital Boston Verfahren zur behandlung und prävention von kolitis, an der il-13 und nk-t zellen beteiligt sind
US7368142B2 (en) * 2002-08-01 2008-05-06 Renew Life Formulas, Inc. Natural sweetener
JP2006511462A (ja) 2002-08-27 2006-04-06 ソシエテ デ プロデユイ ネツスル ソシエテ アノニム 上皮組織損傷又は脱毛症の予防又は治療
AU2003277021A1 (en) 2002-09-27 2004-04-19 Biomira, Inc. Glycosylceramide analogues
US9717754B2 (en) * 2003-02-27 2017-08-01 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
US20040171522A1 (en) * 2003-02-27 2004-09-02 Yaron Ilan Regulation of immune responses by manipulation of intermediary metabolite levels
WO2005032462A2 (en) 2003-02-27 2005-04-14 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
US20040235162A1 (en) * 2003-03-18 2004-11-25 Kirin Beer Kabushiki Kaisha Method of preparing immunoregulatory dendritic cells and the use thereof
US20050032210A1 (en) * 2003-03-18 2005-02-10 Kirin Beer Kabushiki Kaisha Method of preparing immuno-regulatory dendritic cells and the use thereof
AU2003225891A1 (en) 2003-03-20 2004-11-19 Brigham Young University 6"-amino-6"-deoxygalactosylceramides
WO2004084874A2 (en) 2003-03-24 2004-10-07 Brigham And Women's Hospital, Inc. Mtp inhibitors for inhibiting inflammation
EP1653977A2 (en) 2003-07-17 2006-05-10 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Treatment of disorders associated with natural killer t cells
AU2005251589B2 (en) * 2004-06-11 2011-01-06 Riken Drug having regulatory cell ligand contained in liposome

Also Published As

Publication number Publication date
JP4948418B2 (ja) 2012-06-06
EP1812015A2 (en) 2007-08-01
US7682614B2 (en) 2010-03-23
CN101031307B (zh) 2012-09-05
ATE539757T1 (de) 2012-01-15
US20100197613A1 (en) 2010-08-05
AU2005310247A1 (en) 2006-06-08
EP1812015A4 (en) 2008-02-20
WO2006060117A2 (en) 2006-06-08
EP1812015B1 (en) 2012-01-04
JP2008518974A (ja) 2008-06-05
ES2378076T3 (es) 2012-04-04
US20060116332A1 (en) 2006-06-01
CA2584971C (en) 2013-08-06
US8679499B2 (en) 2014-03-25
CA2584971A1 (en) 2006-06-08
PT1812015E (pt) 2012-02-20
CN101031307A (zh) 2007-09-05
WO2006060117A3 (en) 2007-03-01

Similar Documents

Publication Publication Date Title
DK1812015T3 (en) Methods for inhibition of nkt cells
Cripps et al. MDSC in autoimmunity
Fujio et al. Structure-based discovery of glycolipids for CD1d-mediated NKT cell activation: tuning the adjuvant versus immunosuppression activity
Ip et al. Cycloastragenol is a potent telomerase activator in neuronal cells: implications for depression management
WO2008137758A3 (en) Amino acid lipids and uses thereof
Jervis et al. New CD1d agonists: synthesis and biological activity of 6 ″-triazole-substituted α-galactosyl ceramides
WO2004074434A3 (en) Methods and compositions for administering therapeutic and diagnostic agents
UA117216C2 (uk) Пухлиноасоційований пептид та його застосування
BR112013026114A2 (pt) composições nutricionais que incluem ácidos graxos de cadeia ramificada e processos de utilização das mesmas
WO2009086504A3 (en) Collagen formulations for improved skin care
MX2009003305A (es) Inhibidores de co-transportador de glucosa de sodio 2 y metodo para su uso.
AR064220A1 (es) Formulacion liofilizada mab abeta
MX2009002937A (es) Metodo y sistema para infusion controlada de substancias terapeuticas.
BR112014032999A2 (pt) optimização de anticorpos que ligam o gene de ativação de linfócito 3 (lag-3), e uso dos mesmos
BR112015021470A2 (pt) conjugado de polímero para administração de um agente bioativo
WO2009151708A3 (en) Peptide analogs of alpha-melanocyte stimulating hormone
Guiard et al. Fatty acyl structures of Mycobacterium tuberculosis sulfoglycolipid govern T cell response
MX2009002787A (es) Composiciones y métodos para prevenir el cáncer con cupredoxinas.
Chen et al. Hydrogen treatment protects mice against chronic pancreatitis by restoring regulatory T cells loss
KR20080035997A (ko) 글루코사민 또는 글루코사민 유도체를 포함하는 아토피성피부염 치료용 조성물 및 이를 사용하여 아토피성 피부염을치료하는 방법
WO2018033941A3 (en) Pharmaceutical compositions of ibrutinib
Hogan et al. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide
Pareek et al. Melittin as a therapeutic agent for rheumatoid arthritis: mechanistic insights, advanced delivery systems, and future perspectives
BRPI0409790A (pt) 7-azaindóis e seu uso como terapêuticos
Yin et al. Immune cell senescence in autoimmunity: implications for disease pathogenesis and therapeutic targeting